Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human...

Area of Science:

• Oncolytic virotherapy
• Cancer genetics
• Virology

Background:

• Oncolytic virotherapy utilizes replicating viruses for cancer treatment.
• Ideal oncolytic agents should selectively target cancer cells based on genetic abnormalities.
• Zinc-finger antiviral protein (ZAP) deficiency is a potential target for selective viral therapies.

Purpose of the Study:

• To identify a novel oncolytic virus with cancer-selective properties.
• To investigate the role of ZAP deficiency in viral selectivity.
• To evaluate the therapeutic potential of the identified virus in preclinical models.

Main Methods:

• Identification of a naturally occurring alphavirus (M1) with oncolytic properties.
• In vitro, in vivo, and ex vivo studies to assess M1 efficacy and tropism.
• Systematic analysis to determine M1 selectivity based on ZAP deficiency.
• Multicenter pathology study using tissue microarrays to assess ZAP expression in human cancers.

Main Results:

• M1 demonstrated potent oncolytic efficacy and high tumor tropism.
• M1 selectivity was confirmed to be dependent on ZAP deficiency.
• A large-scale study revealed common ZAP deficiency in human cancers.
• M1 induced endoplasmic reticulum stress-mediated apoptosis in cancer cells.

Conclusions:

• Naturally occurring alphavirus M1 is a novel oncolytic agent targeting ZAP-deficient cancers.
• The common deficiency of ZAP in human cancers suggests broad applicability for M1.
• M1-induced apoptosis via endoplasmic reticulum stress offers insights into its mechanism of action.
• This study provides a foundation for personalized cancer therapy using oncolytic viruses.